Literature DB >> 33077852

The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites.

Francesco Bartoli1, Błażej Misiak2, Tommaso Callovini3, Daniele Cavaleri3, Riccardo M Cioni3, Cristina Crocamo3, Jonathan B Savitz4,5, Giuseppe Carrà3,6.   

Abstract

Growing evidence suggests that a dysregulation of the kynurenine pathway (KP) occurs in bipolar disorder (BD). This systematic review and meta-analysis aimed at assessing the possible differences in peripheral blood levels of KP metabolites between individuals with BD and healthy controls. We searched Medline, Embase, and PsycInfo electronic databases for articles indexed up to February 2020. We included any observational study comparing the peripheral blood levels of at least one KP metabolite between adults with BD and healthy controls. Random-effects meta-analyses were carried out generating pooled standardized mean differences (SMDs). Heterogeneity between studies was estimated using the I2 index. Meta-regression and sensitivity analyses were conducted. Sixteen studies met inclusion criteria and were included in our study. Meta-analyses showed that individuals with BD have lower peripheral blood levels of tryptophan (SMD = -0.29), kynurenine (SMD = -0.28), kynurenic acid (SMD = -0.30), and xanthurenic acid (SMD = -0.55), along with lower kynurenic acid to kynurenine (SMD = -0.60) and kynurenic acid to quinolinic acid (SMD = -0.37) ratios, than healthy controls. Individuals with a manic episode showed the greatest reductions in tryptophan levels (SMD = -0.51), whereas kynurenic acid levels were more reduced among subjects in a depressive phase (SMD = -0.70). Meta-regression and sensitivity analyses confirmed our results. The findings of the present meta-analysis support the hypothesis of an abnormality of the KP in BD. Considering the partial inconsistency of the findings and the small-to-medium magnitude of the estimated effect sizes, additional research assessing possible mediators or confounders is needed.
© 2020. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33077852     DOI: 10.1038/s41380-020-00913-1

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  64 in total

Review 1.  Neurobiological trait abnormalities in bipolar disorder.

Authors:  C Langan; C McDonald
Journal:  Mol Psychiatry       Date:  2009-05-19       Impact factor: 15.992

Review 2.  Inflammation-associated depression: from serotonin to kynurenine.

Authors:  Robert Dantzer; Jason C O'Connor; Marcus A Lawson; Keith W Kelley
Journal:  Psychoneuroendocrinology       Date:  2010-10-30       Impact factor: 4.905

Review 3.  Targeting the immune system in the treatment of bipolar disorder.

Authors:  Joshua D Rosenblat
Journal:  Psychopharmacology (Berl)       Date:  2019-02-13       Impact factor: 4.530

Review 4.  Biological hypotheses and biomarkers of bipolar disorder.

Authors:  Ekaterina Sigitova; Zdeněk Fišar; Jana Hroudová; Tereza Cikánková; Jiří Raboch
Journal:  Psychiatry Clin Neurosci       Date:  2017-01-06       Impact factor: 5.188

Review 5.  A systematic review of evidence for the role of inflammatory biomarkers in bipolar patients.

Authors:  Pavani Sayana; Gabriela Delevati Colpo; Lutiana R Simões; Vijayasree Vayalanellore Giridharan; Antonio Lucio Teixeira; João Quevedo; Tatiana Barichello
Journal:  J Psychiatr Res       Date:  2017-03-29       Impact factor: 4.791

6.  The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013.

Authors:  Alize J Ferrari; Emily Stockings; Jon-Paul Khoo; Holly E Erskine; Louisa Degenhardt; Theo Vos; Harvey A Whiteford
Journal:  Bipolar Disord       Date:  2016-08       Impact factor: 6.744

Review 7.  L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.

Authors:  Hidetsugu Fujigaki; Yasuko Yamamoto; Kuniaki Saito
Journal:  Neuropharmacology       Date:  2016-01-06       Impact factor: 5.250

Review 8.  Bipolar Disorder.

Authors:  Andre F Carvalho; Joseph Firth; Eduard Vieta
Journal:  N Engl J Med       Date:  2020-07-02       Impact factor: 91.245

Review 9.  The kynurenine pathway: a finger in every pie.

Authors:  Jonathan Savitz
Journal:  Mol Psychiatry       Date:  2019-04-12       Impact factor: 15.992

Review 10.  The Emerging Neurobiology of Bipolar Disorder.

Authors:  Paul J Harrison; John R Geddes; Elizabeth M Tunbridge
Journal:  Trends Neurosci       Date:  2017-11-20       Impact factor: 13.837

View more
  14 in total

1.  Multi-omics analyses of serum metabolome, gut microbiome and brain function reveal dysregulated microbiota-gut-brain axis in bipolar depression.

Authors:  Zhiming Li; Jianbo Lai; Peifen Zhang; Jiahong Ding; Jiajun Jiang; Chuanfa Liu; Huimin Huang; Hefu Zhen; Caixi Xi; Yuzhe Sun; Lingling Wu; Lifang Wang; Xingle Gao; Yan Li; Yaoyang Fu; Zhuye Jie; Shenghui Li; Danhua Zhang; Yiqing Chen; Yiyi Zhu; Shaojia Lu; Jing Lu; Dandan Wang; Hetong Zhou; Xiuxia Yuan; Xue Li; Lijuan Pang; Manli Huang; Huanming Yang; Wenwei Zhang; Susanne Brix; Karsten Kristiansen; Xueqin Song; Chao Nie; Shaohua Hu
Journal:  Mol Psychiatry       Date:  2022-04-20       Impact factor: 15.992

Review 2.  Phenotypes, mechanisms and therapeutics: insights from bipolar disorder GWAS findings.

Authors:  Ming Li; Tao Li; Xiao Xiao; Jun Chen; Zhonghua Hu; Yiru Fang
Journal:  Mol Psychiatry       Date:  2022-03-29       Impact factor: 15.992

Review 3.  An Emerging Cross-Species Marker for Organismal Health: Tryptophan-Kynurenine Pathway.

Authors:  Laiba Jamshed; Amrita Debnath; Shanza Jamshed; Jade V Wish; Jason C Raine; Gregg T Tomy; Philippe J Thomas; Alison C Holloway
Journal:  Int J Mol Sci       Date:  2022-06-04       Impact factor: 6.208

4.  Focus on Peripheral Biomarkers of Mental Disorders.

Authors:  Francesco Bartoli; Giuseppe Carrà
Journal:  Brain Sci       Date:  2022-06-08

5.  Acute administration of ibuprofen increases serum concentration of the neuroprotective kynurenine pathway metabolite, kynurenic acid: a pilot randomized, placebo-controlled, crossover study.

Authors:  Jonathan Savitz; Bart N Ford; Rayus Kuplicki; Sahib Khalsa; T Kent Teague; Martin P Paulus
Journal:  Psychopharmacology (Berl)       Date:  2022-10-22       Impact factor: 4.415

6.  Metabolomic Identification of Serum Exosome-Derived Biomarkers for Bipolar Disorder.

Authors:  Yang Du; Ji-Hui Dong; Lei Chen; Hua Liu; Guang-En Zheng; Guang-Yang Chen; Yong Cheng
Journal:  Oxid Med Cell Longev       Date:  2022-01-10       Impact factor: 6.543

7.  Multiomic profiling of iron-deficient infant monkeys reveals alterations in neurologically important biochemicals in serum and cerebrospinal fluid before the onset of anemia.

Authors:  Brian J Sandri; Jonathan Kim; Gabriele R Lubach; Eric F Lock; Candace Guerrero; LeeAnn Higgins; Todd W Markowski; Pamela J Kling; Michael K Georgieff; Christopher L Coe; Raghavendra B Rao
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2022-03-10       Impact factor: 3.210

Review 8.  The Kynurenine Pathway in Traumatic Brain Injury: Implications for Psychiatric Outcomes.

Authors:  Timothy B Meier; Jonathan Savitz
Journal:  Biol Psychiatry       Date:  2021-05-31       Impact factor: 13.382

9.  Tryptophan Catabolites in Bipolar Disorder: A Meta-Analysis.

Authors:  Kaat Hebbrecht; Katrien Skorobogatov; Erik J Giltay; Violette Coppens; Livia De Picker; Manuel Morrens
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

10.  Increased Kynurenine Indicates a Fatal Course of COVID-19.

Authors:  Harald Mangge; Markus Herrmann; Andreas Meinitzer; Sabine Pailer; Pero Curcic; Zdenka Sloup; Magdalena Holter; Florian Prüller
Journal:  Antioxidants (Basel)       Date:  2021-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.